You are here

FDA Approves Tolsura for Systemic Fungal Infections

New Antifungal Has Increased Bioavailability and Reduced Variability

The FDA has approved the new drug application for Tolsura (SUBA-itraconazole, Mayne Pharma). SUBA-itraconazole is indicated for the treatment of certain systemic fungal infections in adult patients.

The new formulation of traconazole is indicated for the treatment of blastomycosis, pulmonary and extrapulmonary; histoplasmosis, including chronic cavitary pulmonary disease and disseminated, nonmeningeal histoplasmosis; and aspergillosis, pulmonary and extrapulmonary, in patients who are intolerant of or refractory to amphotericin B therapy.

These serious infections most commonly occur in vulnerable or immunocompromised patients, for example, those with a history of cancer, transplants, HIV/AIDS, or chronic rheumatic disorders.

Among the most common adverse reactions are nausea, rash, vomiting, edema, headache, diarrhea, fatigue, fever, pruritus, and hypertension.

SUBA-itraconazole 65-mg tablets are expected to be available in January 2019.

Sources: Specialty Pharmacy Times, December 13, 2018;, December 11, 2018

Recent Headlines

First Devices Cleared for Diagnostic Testing Via Throat, Rectum Specimens
First New Medication for Seizure Clusters in More Than Two Decades
Novel, Low-cost Device Highly Accurate at Screening Newborn Jaundice
Mode Delivers Antivirals Safely, Cheaply to Remote Regions
Averts Disease Worsening, Reduces Potential for Blindness
Risk May Remain for 6 Months After Treatment
FDA Removes Boxed Warning With Drug’s Fifth Approval
Overeager Use of Recommendations Creates Problems
Artificial Intelligence Enables Platform to Detect Amyloid PET Status